Overview

Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects

Status:
Completed
Trial end date:
2016-07-13
Target enrollment:
Participant gender:
Summary
To assess the effect of PEX168 doses on the pharmacokinetics of warfarin in healthy subjects.To provide a scientific basis for clinical drug combination of PEX168. To evaluated the impact of pharmacodynamics coadministrated hypodermic PEX168 and warfarin in healthy subjects. To assess the safety of single doses of warfarin administered with and without PEX168
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Treatments:
Warfarin